CN111542339B - 疫苗 - Google Patents
疫苗 Download PDFInfo
- Publication number
- CN111542339B CN111542339B CN201880071229.0A CN201880071229A CN111542339B CN 111542339 B CN111542339 B CN 111542339B CN 201880071229 A CN201880071229 A CN 201880071229A CN 111542339 B CN111542339 B CN 111542339B
- Authority
- CN
- China
- Prior art keywords
- vaccine
- polysaccharide
- defatted
- coxiella burnetii
- immunogenic carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 89
- 150000004676 glycans Chemical class 0.000 claims abstract description 69
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 69
- 239000005017 polysaccharide Substances 0.000 claims abstract description 69
- 241000606678 Coxiella burnetii Species 0.000 claims abstract description 42
- 239000002158 endotoxin Substances 0.000 claims abstract description 37
- 208000015181 infectious disease Diseases 0.000 claims abstract description 37
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 37
- 230000002163 immunogen Effects 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 25
- 210000002421 cell wall Anatomy 0.000 claims abstract description 21
- 208000024891 symptom Diseases 0.000 claims abstract description 21
- 206010037688 Q fever Diseases 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 206010037660 Pyrexia Diseases 0.000 claims description 16
- 229960000814 tetanus toxoid Drugs 0.000 claims description 15
- 150000002632 lipids Chemical class 0.000 claims description 11
- 241001445332 Coxiella <snail> Species 0.000 claims description 8
- 239000003431 cross linking reagent Substances 0.000 claims description 8
- 231100000252 nontoxic Toxicity 0.000 claims description 8
- 230000003000 nontoxic effect Effects 0.000 claims description 8
- 230000002480 immunoprotective effect Effects 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract description 32
- 108010060123 Conjugate Vaccines Proteins 0.000 abstract description 17
- 229940031670 conjugate vaccine Drugs 0.000 abstract description 17
- 230000003053 immunization Effects 0.000 abstract description 2
- 238000002649 immunization Methods 0.000 abstract description 2
- 241000700198 Cavia Species 0.000 description 35
- 241001465754 Metazoa Species 0.000 description 33
- 239000012071 phase Substances 0.000 description 23
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 12
- 108010078791 Carrier Proteins Proteins 0.000 description 12
- 102000014914 Carrier Proteins Human genes 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 10
- 241000700199 Cavia porcellus Species 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 210000001325 yolk sac Anatomy 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000004579 body weight change Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- -1 virenose) Chemical class 0.000 description 4
- AWWDAEYRNORHRF-BWBBJGPYSA-N (2r,3r,4s,5r)-2,3,4,5-tetrahydroxy-3-methylhexanal Chemical compound C[C@@H](O)[C@H](O)[C@@](C)(O)[C@@H](O)C=O AWWDAEYRNORHRF-BWBBJGPYSA-N 0.000 description 3
- VXRTVNQXTKPQDQ-UHFFFAOYSA-N 1alpha,15-Dihydroxymarasmene Natural products CC1OC(O)C(O)C(C)(O)C1O VXRTVNQXTKPQDQ-UHFFFAOYSA-N 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000011969 continuous reassessment method Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 101150044687 crm gene Proteins 0.000 description 3
- 238000005238 degreasing Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108700000434 Cannabis sativa edestin Proteins 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 241000193468 Clostridium perfringens Species 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108010040473 pneumococcal surface protein A Proteins 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- NOXFMRMRRUXMEJ-NQYRFPRJSA-N (2R)-2-[[(2S)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]propanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H](C)C(=O)N[C@H](CCC(N)=O)C(=O)O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO NOXFMRMRRUXMEJ-NQYRFPRJSA-N 0.000 description 1
- OGLCQHRZUSEXNB-UAPNVWQMSA-N (2r,3r,3ar,6ar)-2,3,6-trihydroxy-3,3a,6,6a-tetrahydro-2h-furo[3,2-b]furan-5-one Chemical compound OC1C(=O)O[C@@H]2[C@@H](O)[C@H](O)O[C@@H]21 OGLCQHRZUSEXNB-UAPNVWQMSA-N 0.000 description 1
- VXRTVNQXTKPQDQ-RYQSKDSCSA-N (3r,4r,5s,6r)-4,6-dimethyloxane-2,3,4,5-tetrol Chemical compound C[C@H]1OC(O)[C@H](O)[C@](C)(O)[C@H]1O VXRTVNQXTKPQDQ-RYQSKDSCSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- CFDRQRFAQCJPBZ-UHFFFAOYSA-N 1-chlorohexan-1-ol Chemical compound CCCCCC(O)Cl CFDRQRFAQCJPBZ-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 241000209205 Coix Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 150000000782 D-glucoses Chemical class 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000009701 Embryo Loss Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001523956 Parengyodontium album Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 108700012261 Rotavirus VP7 Proteins 0.000 description 1
- 101710151387 Serine protease 1 Proteins 0.000 description 1
- 102100032491 Serine protease 1 Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 101710119665 Trypsin-1 Proteins 0.000 description 1
- 206010062910 Vascular infections Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 108010031071 cholera toxoid Proteins 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017904499A AU2017904499A0 (en) | 2017-11-06 | Vaccine | |
AU2017904499 | 2017-11-06 | ||
PCT/AU2018/051200 WO2019084632A1 (en) | 2017-11-06 | 2018-11-06 | Vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111542339A CN111542339A (zh) | 2020-08-14 |
CN111542339B true CN111542339B (zh) | 2024-06-04 |
Family
ID=66331160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880071229.0A Active CN111542339B (zh) | 2017-11-06 | 2018-11-06 | 疫苗 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11045536B2 (zh) |
EP (1) | EP3706787A4 (zh) |
JP (1) | JP7311103B2 (zh) |
CN (1) | CN111542339B (zh) |
AU (1) | AU2018359019A1 (zh) |
CA (1) | CA3081769A1 (zh) |
WO (1) | WO2019084632A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL2023863B1 (en) * | 2019-09-20 | 2021-05-25 | Univ Griffith | Protein particles and uses thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1288384A (zh) * | 1998-01-13 | 2001-03-21 | 美国国有健康与人类服务部 | 用于预防哺乳动物粘膜炎莫拉氏(布拉汉氏)菌感染的脂寡糖疫苗 |
US6858211B1 (en) * | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
AU2005253864A1 (en) * | 2004-06-22 | 2005-12-29 | Daiichi Sankyo Company, Limited | Q fever vaccine preparation and method of producing the vaccine |
WO2010096640A2 (en) * | 2009-02-20 | 2010-08-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method and compositions for host cell-free growth of pathogens |
CN102139100A (zh) * | 2011-01-05 | 2011-08-03 | 中国人民解放军军事医学科学院微生物流行病研究所 | 蛋白Mip在对贝氏柯克斯体的免疫保护中的应用 |
CN103124737A (zh) * | 2010-03-11 | 2013-05-29 | 葛兰素史密丝克莱恩生物有限公司 | 针对革兰氏阴性菌例如奈瑟菌属感染或疾病的免疫原性组合物或疫苗 |
CN105188743A (zh) * | 2013-03-18 | 2015-12-23 | 葛兰素史密丝克莱恩生物有限公司 | 治疗方法 |
CN105744951A (zh) * | 2013-08-24 | 2016-07-06 | 巴拉特生物技术国际有限公司 | 细菌疫苗及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1976857A4 (en) * | 2006-01-13 | 2011-08-03 | Baxter Int | PROCESS FOR CLEANING POLYSACCHARIDES |
WO2007106073A2 (en) * | 2006-03-02 | 2007-09-20 | University Of Massachusetts | Modified pathogens for use as vaccines |
US9422545B2 (en) * | 2013-07-23 | 2016-08-23 | The Curators Of The University Of Missouri | Lipopolysaccharide-targeted peptide mimic vaccine against Q fever |
-
2018
- 2018-11-06 CN CN201880071229.0A patent/CN111542339B/zh active Active
- 2018-11-06 AU AU2018359019A patent/AU2018359019A1/en active Pending
- 2018-11-06 CA CA3081769A patent/CA3081769A1/en active Pending
- 2018-11-06 EP EP18872061.9A patent/EP3706787A4/en active Pending
- 2018-11-06 JP JP2020519095A patent/JP7311103B2/ja active Active
- 2018-11-06 WO PCT/AU2018/051200 patent/WO2019084632A1/en unknown
- 2018-11-06 US US16/762,067 patent/US11045536B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1288384A (zh) * | 1998-01-13 | 2001-03-21 | 美国国有健康与人类服务部 | 用于预防哺乳动物粘膜炎莫拉氏(布拉汉氏)菌感染的脂寡糖疫苗 |
US6858211B1 (en) * | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
AU2005253864A1 (en) * | 2004-06-22 | 2005-12-29 | Daiichi Sankyo Company, Limited | Q fever vaccine preparation and method of producing the vaccine |
WO2010096640A2 (en) * | 2009-02-20 | 2010-08-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method and compositions for host cell-free growth of pathogens |
CN103124737A (zh) * | 2010-03-11 | 2013-05-29 | 葛兰素史密丝克莱恩生物有限公司 | 针对革兰氏阴性菌例如奈瑟菌属感染或疾病的免疫原性组合物或疫苗 |
CN102139100A (zh) * | 2011-01-05 | 2011-08-03 | 中国人民解放军军事医学科学院微生物流行病研究所 | 蛋白Mip在对贝氏柯克斯体的免疫保护中的应用 |
CN105188743A (zh) * | 2013-03-18 | 2015-12-23 | 葛兰素史密丝克莱恩生物有限公司 | 治疗方法 |
CN105744951A (zh) * | 2013-08-24 | 2016-07-06 | 巴拉特生物技术国际有限公司 | 细菌疫苗及其制备方法 |
Non-Patent Citations (11)
Title |
---|
A monoclonal antibody specific for a unique biomarker, virenose, in a lipopolysaccharide of Coxiella burnetii;K. Palkovicova等;《Clinical Microbiology and Infection》;20091231;第15卷;第183-184页 * |
An O-Specific Polysaccharide/Tetanus Toxoid Conjugate Vaccine Induces Protection in Guinea Pigs against Virulent Challenge with Coxiella burnetii;Stephen R Graves;《Vaccines (Basel) .》;第10卷(第9期);第1-12页 * |
In silico biosynthesis of virenose, a methylated deoxy-sugar unique to Coxiella burnetii lipopolysaccharide;Gabriela Flores-Ramirez等;《Proteome Sci》;20121115;第10卷(第1期);第1-8页 * |
PAVOL VADOVIC等.Structural and Functional Characterization of the Glycan Antigens Involved in Immunobiology of Q Fever.《ANNALS NEW YORK ACADEMY OF SCIENCES》.2005,第1063卷 * |
Phase Variation Analysis of Coxiella burnetii during Serial Passage in Cell Culture by Use of Monoclonal Antibodies;Akitoyo Hotta等;《Infect Immun》;20020831;第70卷(第8期);第4747-4749页 * |
Q热疫苗研究进展;魏文进等;《微生物免疫学进展》;第32卷(第3期);第64-67页 * |
Recent progress in glycomics and proteomics of the Q fever bacterium Coxiella burnetii;R Toman等;《Acta Virol》;20131231;第57卷(第2期);第229-237页 * |
RUDOLF TOMAN等.Studies on the Immunological Role of Virenose and Dihydrohydroxystreptose Present in the Coxiella burnetii Phase I Lipopolysaccharide.《Ann. N.Y. Acad. Sci》.2003,第99卷 * |
Structural and Functional Characterization of the Glycan Antigens Involved in Immunobiology of Q Fever;PAVOL VADOVIC等;《ANNALS NEW YORK ACADEMY OF SCIENCES》;20051231;第1063卷;第149-153页 * |
Studies on the Immunological Role of Virenose and Dihydrohydroxystreptose Present in the Coxiella burnetii Phase I Lipopolysaccharide;RUDOLF TOMAN等;《Ann. N.Y. Acad. Sci》;20031231;第99卷;第505-509页 * |
贝氏柯克斯体的相变异与脂多糖研究进展;王涛;《国际检验医学杂志》;第37卷(第17期);第2431-2433页 * |
Also Published As
Publication number | Publication date |
---|---|
EP3706787A1 (en) | 2020-09-16 |
CA3081769A1 (en) | 2019-05-09 |
WO2019084632A1 (en) | 2019-05-09 |
JP7311103B2 (ja) | 2023-07-19 |
EP3706787A4 (en) | 2021-10-20 |
US11045536B2 (en) | 2021-06-29 |
US20200345824A1 (en) | 2020-11-05 |
AU2018359019A1 (en) | 2020-04-09 |
JP2021502957A (ja) | 2021-02-04 |
CN111542339A (zh) | 2020-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0118831B1 (en) | Vaccines for gram-negative bacteria and method for the preparation thereof | |
Milner et al. | General characteristics | |
JP5745221B2 (ja) | タンパク質マトリックスワクチンおよびそのようなワクチンの製造方法および投与方法 | |
JP5781542B2 (ja) | E.coliキャリアタンパク質に結合体化した多糖免疫原 | |
RU2579900C2 (ru) | Очистка капсульных сахаридов staphylococcus aureus типа 5 и типа 8 | |
JP5344558B2 (ja) | カチオン性ナノゲルを用いる粘膜ワクチン | |
KR102144602B1 (ko) | 새로운 점막 보조제 및 전달 시스템 | |
WO1980000412A1 (en) | Pasteurellosis vaccines | |
TW201946650A (zh) | 針對腹內感染之疫苗 | |
JP2013504588A (ja) | 免疫原性の高いタンパク質マトリックスワクチン | |
NZ223841A (en) | Iron-restriction proteins from pasteurella, vaccines and antibodies | |
CN111542339B (zh) | 疫苗 | |
Byrd et al. | Protective efficacy of conjugate vaccines against experimental challenge with porcine Actinobacillus pleuropneumoniae | |
CN102497879A (zh) | 单时疫苗 | |
RU2563354C2 (ru) | Адъювант на основе низкомолекулярного пептидогликана клеточной стенки бактерий | |
AU733845B2 (en) | Immunogenic complex, use, method of preparation thereof and vaccine containing same | |
Fournier et al. | Murine immunoprotective activity of Klebsiella pneumoniae cell surface preparations: comparative study with ribosomal preparations | |
ES2686875T3 (es) | Exopolisacárido de la bacteria Shigella sonnei, método para producirlo, vacuna y composición farmacéutica que lo contienen | |
CN115996751A (zh) | 与离子液体佐剂有关的方法和组合物 | |
Sironmani | Nano-formulations for Diagnostics and Therapeutics of Foot-and-Mouth Disease in Animals | |
CN116898960A (zh) | 细菌多糖蛋白缀合物及其应用 | |
Akter et al. | Glycoconjugate Vaccine: An Effective Way to Combat Infectious Diseases and Cancers | |
TRUSZCZYNSKI | Evaluation of the immunogenicity of the vaccine against Pasteurella multocida infections in calves | |
Carrasco Medina | Investigation of a leukotoxin containing immune stimulating complex (ISCOM) vaccine and early immunization in dairy calves | |
JPH02101023A (ja) | オーエスキー病のサブユニットワクチン、及び製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: New South Wales,Australia Applicant after: Stephen Roger graves Applicant after: John Steiner Applicant after: Moira Cecilia graves Applicant after: Rudolph Thoman Applicant after: Rodney cabis Applicant after: The New South Wales government represented by the Department of Planning, Industry, and Environment's Department of Primary Industries Address before: New South Wales,Australia Applicant before: Stephen Roger graves Applicant before: John Steiner Applicant before: Moira Cecilia graves Applicant before: Rudolph Thoman Applicant before: Rodney cabis Applicant before: The New South Wales government represented by the Department of Planning and Industry's Department of Primary Industries |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230530 Address after: Vitoria, Australia Applicant after: OZQ Private Ltd. Address before: New South Wales,Australia Applicant before: Stephen Roger graves Applicant before: John Steiner Applicant before: Moira Cecilia graves Applicant before: Rudolph Thoman Applicant before: Rodney cabis Applicant before: The New South Wales government represented by the Department of Planning, Industry, and Environment's Department of Primary Industries Effective date of registration: 20230530 Address after: New South Wales,Australia Applicant after: Stephen Roger graves Applicant after: John Steiner Applicant after: Moira Cecilia graves Applicant after: Rudolph Thoman Applicant after: Rodney cabis Applicant after: The New South Wales government represented by the Department of Planning and Industry's Department of Primary Industries Address before: New South Wales,Australia Applicant before: Stephen Roger graves Applicant before: John Steiner Applicant before: Moira Cecilia graves Applicant before: Rudolph Thoman Applicant before: Rodney cabis Applicant before: The government of New South Wales represented by the Ministry of primary industry as the office of the Ministry of industry |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |